You have the right question but the wrong implication. MNKD would not waste the time and $$$ to initiate the 30 mg study if there were problems w/ the current studies. They would conserve cash to fund response to FDA concerns. IMO if they had the results in hand when they initiated this study it is a very bullish signal.